The new facility will be the first of its kind in the United States, although the company has a facility in Cork, Ireland, that produces nitrocellulose membrane. The company estimates the plant will create about 60 manufacturing jobs, according to Bloom-Baglin. MilliporeSigma has already begun planning construction of the facility, which is expected to be operational in late 2024. "MilliporeSigma's new lateral flow membrane facility will increase domestic supply, help alleviate shortage concerns, and add to the United States' pandemic preparedness and response."
"Worldwide market demand for membrane exceeds supply, and there is limited production capacity in the United States," said Rachel Bloom-Baglin, head of PR for MilliporeSigma. It will be the first MilliporeSigma plant in the U.S. The new Sheboygan facility will produce nitrocellulose membrane, a material used in COVID-19 rapid antigen tests. The life science business operates manufacturing sites around the globe that make lab materials and technologies for scientists.
MilliporeSigma is part of the life science division of the German-based company Merck KGaA. Department of Defense, in coordination with the Department of Health and Human Services, awarded MilliporeSigma a $136.7 million contract Dec. SHEBOYGAN - MilliporeSigma is building a new facility on its Sheboygan Falls campus to manufacture a component of COVID-19 rapid tests.
0 kommentar(er)
